PTC Therapeutics, Inc.
NASDAQ:PTCTBiotechnology
+$0.60 today
- Market cap
- $5.03B
- Beta
- 0.55
- P/E (TTM)
- -35.0
- EPS (TTM)
- -$2.26
Volume 0.64M
Average 1.27M
PTCT Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
PTC Therapeutics, Inc.NASDAQ: PTCT
Gross Profit · Q2 FY2026 · quarter ended Jun 2026
Gross profit growth accelerates
Q2 FY2026 gross profit of $340.6M rose 103.4% year over year, ahead of the -51.6% change in trailing-twelve-month gross profit. Sequentially, it rose 39.3% from the prior quarter. Over 3 fiscal years it compounded at +36.4% a year.
Context
- Gross profit amounted to 95.9% of revenue in FY2025, up 3.0 pp from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +103.4% holds above the trailing-twelve-month pace of -51.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 1.66B USD
- Year-over-year change
- +121.4%
- 4-year CAGR
- +34.5%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.66B | +121.4% |
| FY2024 | 2024-12-31 | 749.38M | -14.1% |
| FY2023 | 2023-12-31 | 872.34M | +33.4% |
| FY2022 | 2022-12-31 | 654.12M | +29.2% |
| FY2021 | 2021-12-31 | 506.27M | — |
Gross Profit vs competitors
How PTCT compares with its peers on the latest reported figures
- PTCT's LTM Jun 2026 gross profit of $828.57M is the 4th highest of the 11 companies compared; the peer median is $485.29M.
- Its year-over-year change of -51.6% is the 9th highest of 10, against a peer median of -1.3%.
- Gross profit amounts to 82.1% of revenue for PTCT, versus a peer median of 93.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $821.17B | +32536.1% | +16.0% | 79.9% | |
| LTM Mar 2026 | $1.36B | -25.4% | +18.4% | 62.4% | |
| LTM Sep 2026 | $942.72M | -1.3% | +17.4% | 98.2% | |
| LTM Jun 2026 | $828.57M | -51.6% | +36.4% | 82.1% | |
| LTM Jun 2026 | $665.62M | +193.4% | +85.5% | 93.3% | |
| LTM Mar 2026 | $559.44M | +11.3% | +19.0% | 83.6% | |
| LTM Jun 2026 | $411.14M | +22.6% | — | 93.3% | |
| LTM Mar 2026 | $67.34M | -34.5% | +110.2% | 93.8% | |
| LTM Jun 2026 | -$521K | — | — | — | |
| LTM Mar 2026 | -$781K | -91.9% | — | — | |
| LTM Mar 2026 | -$42.41M | -4.9% | — | — | |
| Peer median (excluding PTCT) | $485.29M | -1.3% | +18.7% | 93.3% | |
Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 538.59M | 698.8M | 937.82M | 806.78M | 1.73B |
| Cost of Revenue | 32.33M | 44.68M | 65.49M | 57.4M | 71.76M |
| Gross Profit | 506.27M | 654.12M | 872.34M | 749.38M | 1.66B |
| Gross Margin | 94.0% | 93.6% | 93.0% | 92.9% | 95.9% |
| Research & Development | 540.68M | 651.5M | 666.56M | 534.48M | 455.25M |
| Selling, General & Admin | 285.77M | 326M | 332.54M | 300.91M | 347.14M |
| Operating Expenses | 880.71M | 1.1B | 1.31B | 1.05B | 802.39M |
| Depreciation & Amortization | 64.13M | 128.84M | 236.59M | 75.66M | 38.82M |
| EBITDA | (368.18M) | (367.78M) | (330.34M) | (120.46M) | 887.66M |
| EBITDA Margin | -68.4% | -52.6% | -35.2% | -14.9% | 51.3% |
| Operating Income | (374.44M) | (447.41M) | (439.5M) | (302.57M) | 856.51M |
| Operating Margin | -69.5% | -64.0% | -46.9% | -37.5% | 49.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 86.02M | 90.87M | 129.18M | 166.99M | 152.23M |
| Other Income / Expenses | (143.9M) | (140.08M) | (256.61M) | (60.55M) | (159.89M) |
| Income Before Tax | (518.34M) | (587.49M) | (696.11M) | (363.12M) | 696.62M |
| Pre-Tax Margin | -96.2% | -84.1% | -74.2% | -45.0% | 40.3% |
| Income Tax Expense | 5.56M | (28.47M) | (69.51M) | 176K | 13.98M |
| Net Income | (523.9M) | (559.02M) | (626.6M) | (363.3M) | 682.64M |
| Net Margin | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% |
| EPS (Basic) | (7.43) | (7.79) | (8.37) | (4.73) | 8.58 |
| EPS (Diluted) | (7.43) | (7.79) | (8.37) | (4.73) | 7.78 |
| Weighted Avg Shares | 70.47M | 71.73M | 74.84M | 76.85M | 79.53M |
| Weighted Avg Shares (Diluted) | 70.47M | 71.73M | 74.84M | 76.85M | 88.31M |
PTC Therapeutics, Inc.
NASDAQ:PTCT
Intrinsic Alpha fair value
Locked
Current Price
$60.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.